Current Perspectives and Novel Strategies of NRAS-Mutant Melanoma-Reference-Cited by-同舟云学术

Current Perspectives and Novel Strategies of NRAS-Mutant Melanoma

Published:2021-06 Issue: Volume:Volume 14 Page:3709-3719
ISSN:1178-6930
Container-title:OncoTargets and Therapy
language:en
Short-container-title:OTT

Author:

Garcia-Alvarez Alejandro,Ortiz Carolina,Muñoz-Couselo Eva

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Reference80 articles.

1. Global cancer statistics 2020: GLOBOCAN. Available from: https://gco.iarc.fr. Accessed June 7, 2021.

2. Cancer Council. Skin cancer incidence and mortality. Available from: https://wiki.cancer.org.au/skincancerstats/Skin_cancer_incidence_and_mortality. Accessed June 7, 2021.

3. Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell. 2015;161(7):1681–1696. doi:10.1016/j.cell.2015.05.044.

4. Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

5. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Entering the TiME machine: How age-related changes in the tumor immune microenvironment impact melanoma progression and therapy response;Pharmacology & Therapeutics;2024-10

2. Tunlametinib: First Approval;Drugs;2024-07-22

3. RAS G12C Inhibitors: Three Birds with One Stone;Cancer Discovery;2024-05-01

4. A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma;European Journal of Cancer;2024-05

5. The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers;Cancer Discovery;2024-04-19